M Steurer

Summary

Affiliation: University of Innsbruck
Country: Austria

Publications

  1. ncbi Large-vessel arteritis and myelodysplastic syndrome: report of two cases
    M Steurer
    Division of Haematology and Oncology, Innsbruck University Hospital, Innsbruck, Austria
    Eur J Haematol 73:128-33. 2004
  2. ncbi Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis
    Michael Steurer
    Innsbruck Medical University, Division of Hematology and Oncology, Anichstrasse 35, A 6020 Innsbruck, Austria
    Cancer Treat Rev 32:377-89. 2006
  3. ncbi Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey
    Michael Steurer
    Division of Haematology and Oncology, Innsbruck University Hospital, Innsbruck, Austria
    Wien Klin Wochenschr 116:367-72. 2004
  4. ncbi Purine antagonists for chronic lymphocytic leukaemia
    M Steurer
    Innsbruck University Hospital, Division of Haematology and Oncology, Anichstrasse 35, A 6020 Innsbruck, Austria
    Cochrane Database Syst Rev 3:CD004270. 2006
  5. ncbi Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha
    Michael Steurer
    Division of Haematology and Oncology, Innsbruck University Hospital, Anichstrasse 35, A 6020 Innsbruck, Austria
    Br J Haematol 121:101-3. 2003
  6. ncbi Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program
    M Steurer
    Abteilung für Hämatologie and Onkologie, Universitatsklinik fur Innere Medizin, Innsbruck, Austria
    Onkologie 27:150-4. 2004
  7. ncbi Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance
    D Fong
    Division of Hematology and Oncology, Innsbruck Medical University, Austria
    J Clin Pathol 61:31-5. 2008
  8. pmc Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival
    G Spizzo
    Division of Haematology and Oncology, University of Innsbruck, Austria
    Br J Cancer 88:574-8. 2003
  9. pmc Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
    S Hörl
    Division of Virology, Innsbruck Medical University, Innsbruck, Austria
    Leukemia 27:2200-8. 2013
  10. ncbi Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia
    Kathrin Strasser-Weippl
    First Medical Department, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
    Cancer 107:2801-6. 2006

Collaborators

Detail Information

Publications20

  1. ncbi Large-vessel arteritis and myelodysplastic syndrome: report of two cases
    M Steurer
    Division of Haematology and Oncology, Innsbruck University Hospital, Innsbruck, Austria
    Eur J Haematol 73:128-33. 2004
    ..In this clinical setting, steroid therapy may alleviate inflammatory symptoms and result in beneficial hematologic responses...
  2. ncbi Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis
    Michael Steurer
    Innsbruck Medical University, Division of Hematology and Oncology, Anichstrasse 35, A 6020 Innsbruck, Austria
    Cancer Treat Rev 32:377-89. 2006
    ..However, none was able to show a survival advantage. Thus, a systematic Cochrane review may be able to further define the role of purine analogues in the first-line treatment of B-CLL...
  3. ncbi Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey
    Michael Steurer
    Division of Haematology and Oncology, Innsbruck University Hospital, Innsbruck, Austria
    Wien Klin Wochenschr 116:367-72. 2004
    ..Predictive factors for anaemia development and anaemia treatment were also assessed...
  4. ncbi Purine antagonists for chronic lymphocytic leukaemia
    M Steurer
    Innsbruck University Hospital, Division of Haematology and Oncology, Anichstrasse 35, A 6020 Innsbruck, Austria
    Cochrane Database Syst Rev 3:CD004270. 2006
    ..Recent trials suggest improved response rates for purine antagonists compared to alkylator-based regimens in the treatment of B-CLL. However, none was able to show a survival advantage...
  5. ncbi Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha
    Michael Steurer
    Division of Haematology and Oncology, Innsbruck University Hospital, Anichstrasse 35, A 6020 Innsbruck, Austria
    Br J Haematol 121:101-3. 2003
    ..Careful clinical surveillance and thrombosis prophylaxis (heparin or oral anticoagulation) should be considered for MDS patients undergoing combined treatment with thalidomide and erythropoietic growth factors...
  6. ncbi Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program
    M Steurer
    Abteilung für Hämatologie and Onkologie, Universitatsklinik fur Innere Medizin, Innsbruck, Austria
    Onkologie 27:150-4. 2004
    ..Novel therapeutic approaches are thus needed. Thalidomide has recently been recognized as an effective new agent for previously untreated, refractory or relapsed myeloma...
  7. ncbi Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance
    D Fong
    Division of Hematology and Oncology, Innsbruck Medical University, Austria
    J Clin Pathol 61:31-5. 2008
    ..Thus, the aim of this study was to investigate Ep-CAM expression and its potential prognostic impact in pancreatic and ampullary carcinomas...
  8. pmc Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival
    G Spizzo
    Division of Haematology and Oncology, University of Innsbruck, Austria
    Br J Cancer 88:574-8. 2003
    ..7% of tumour specimens and had an additive negative impact on disease-free and overall survival. Determination of both tumour markers should help in guiding new therapeutic strategies in patients with invasive breast cancer...
  9. pmc Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
    S Hörl
    Division of Virology, Innsbruck Medical University, Innsbruck, Austria
    Leukemia 27:2200-8. 2013
    ..Thus, inhibition of fH binding by hSCR18-20 sensitizes CLL cells to CDC and may provide a novel strategy for improving RTX-containing immunochemotherapy of CLL patients. ..
  10. ncbi Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia
    Kathrin Strasser-Weippl
    First Medical Department, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
    Cancer 107:2801-6. 2006
    ..Interphase fluorescent in situ hybridization (FISH) can partly overcome these limitations and increase the sensitivity of cytogenetic assessment in MF...
  11. ncbi Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score
    Kathrin Strasser-Weippl
    First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria
    Leuk Lymphoma 47:441-50. 2006
    ..This is in contrast to previous prognostic scores, in which the poor prognosis group was often very small and/or could not be consistently differentiated from patients with an intermediate prognosis...
  12. ncbi Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients
    Dominik Wolf
    Department of Hematology and Oncology, Innsbruck Medical University, Anichstr 35, 6020 Innsbruck, Austria
    Cancer Immunol Immunother 55:1198-208. 2006
    ..It remains unclear whether this is due to redistribution or active proliferation. The latter would require the upregulation of telomerase activity, whose regulation also remains unknown for Treg...
  13. ncbi Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation
    Michael Steurer
    Division of Haematology and Oncology, University Hospital Innsbruck, Austria
    Hum Pathol 33:253-8. 2002
    ..Moreover, HSTCL seems to occur as a specific late complication of solid organ transplantation...
  14. ncbi Idiopathic myelofibrosis with nodal, serosal and parenchymatous infiltration. Case report and review of the literature
    Alexander Tzankov
    Institute of Pathology, University of Innsbruck, Austria
    Acta Haematol 107:173-6. 2002
    ..The present case demonstrates that IMF not only can progress to acute leukemia but can also spread uncontrollably, or 'metastasize' with extensive sclerosing hematopoietic tumors throughout the body...
  15. ncbi Improving tumor cell detection in pleural effusions by interphase cytogenetics
    Michael Fiegl
    Cytometry B Clin Cytom 55:60-2. 2003
  16. ncbi Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab
    Michael Steurer
    Transplantation 76:435-6. 2003
  17. ncbi Increase of regulatory T cells in the peripheral blood of cancer patients
    Anna Maria Wolf
    Institute for Biomedical Aging Research, Austrian Academy of Sciences, 6020 Innsbruck, Austria
    Clin Cancer Res 9:606-12. 2003
    ..Experimental tumor models in mice revealed that Tregs are potent inhibitors of an antitumor immune response. The current study was designed to determine whether cancer patients exhibit an expanded Treg pool...
  18. ncbi Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor
    Michael Steurer
    Division of Haematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
    Hum Pathol 38:1057-64. 2007
    ..Moreover, we found significantly elevated VEGF expression correlating with MVD, thus suggesting VEGF to play a prominent angiogenic role and representing a novel potential therapeutic target in CIMF...
  19. ncbi The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation
    Gerold Untergasser
    Tumor Biology and Angiogenesis Laboratory, Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
    Int J Cancer 122:1539-47. 2008
    ..Thus, we postulate a novel function of Dkk-3 in endothelial cells as a differentiation factor involved in remodeling the tumor vasculature...
  20. ncbi Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile
    Michael Steurer
    Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
    Cancer 101:2239-46. 2004
    ..In the current study, the authors evaluated the efficacy and tolerability of anagrelide in thrombocytosis associated with myeloproliferative disorders...